Amylyx Pharmaceuticals In... (AMLX)
Amylyx Pharmaceuticals Statistics
Share Statistics
Amylyx Pharmaceuticals has 85.69M shares outstanding. The number of shares has increased by 1.13% in one year.
| Shares Outstanding | 85.69M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.68% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 54.29M |
| Failed to Deliver (FTD) Shares | 500 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 1.57M, so 2.28% of the outstanding shares have been sold short.
| Short Interest | 1.57M |
| Short % of Shares Out | 2.28% |
| Short % of Float | 3.61% |
| Short Ratio (days to cover) | 1.4 |
Valuation Ratios
The PE ratio is 20.09 and the forward PE ratio is -3.37.
| PE Ratio | 20.09 |
| Forward PE | -3.37 |
| PS Ratio | 2.6 |
| Forward PS | 1400.9 |
| PB Ratio | 2.28 |
| P/FCF Ratio | 92.69 |
| PEG Ratio | n/a |
Enterprise Valuation
Amylyx Pharmaceuticals Inc. has an Enterprise Value (EV) of 823.73M.
| EV / Earnings | 16.72 |
| EV / Sales | 2.16 |
| EV / EBITDA | 20.65 |
| EV / EBIT | 21.23 |
| EV / FCF | 77.14 |
Financial Position
The company has a current ratio of 5.66, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.66 |
| Quick Ratio | 5.2 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.97 |
| Cash Flow / Debt | 2.81 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.11% and return on capital (ROIC) is 8.04%.
| Return on Equity (ROE) | 0.11% |
| Return on Assets (ROA) | 0.1% |
| Return on Capital (ROIC) | 8.04% |
| Revenue Per Employee | 991.63K |
| Profits Per Employee | 128.31K |
| Employee Count | 384 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 0.66 |
Taxes
| Income Tax | 5.03M |
| Effective Tax Rate | 0.09 |
Stock Price Statistics
The stock price has increased by -77.71% in the last 52 weeks. The beta is -0.7, so Amylyx Pharmaceuticals 's price volatility has been lower than the market average.
| Beta | -0.7 |
| 52-Week Price Change | -77.71% |
| 50-Day Moving Average | 4.41 |
| 200-Day Moving Average | 3.03 |
| Relative Strength Index (RSI) | 40.57 |
| Average Volume (20 Days) | 1.10M |
Income Statement
In the last 12 months, Amylyx Pharmaceuticals had revenue of 380.79M and earned 49.27M in profits. Earnings per share was 0.73.
| Revenue | 380.79M |
| Gross Profit | 355.35M |
| Operating Income | 38.80M |
| Net Income | 49.27M |
| EBITDA | 39.89M |
| EBIT | 38.80M |
| Earnings Per Share (EPS) | 0.73 |
Balance Sheet
The company has 170.20M in cash and 4.24M in debt, giving a net cash position of 165.96M.
| Cash & Cash Equivalents | 170.20M |
| Total Debt | 4.24M |
| Net Cash | 165.96M |
| Retained Earnings | -304.95M |
| Total Assets | 250.71M |
| Working Capital | 191.35M |
Cash Flow
In the last 12 months, operating cash flow was 11.92M and capital expenditures -1.24M, giving a free cash flow of 10.68M.
| Operating Cash Flow | 11.92M |
| Capital Expenditures | -1.24M |
| Free Cash Flow | 10.68M |
| FCF Per Share | 0.16 |
Margins
Gross margin is 93.32%, with operating and profit margins of 10.19% and 12.94%.
| Gross Margin | 93.32% |
| Operating Margin | 10.19% |
| Pretax Margin | 14.26% |
| Profit Margin | 12.94% |
| EBITDA Margin | 10.48% |
| EBIT Margin | 10.19% |
| FCF Margin | 2.8% |
Dividends & Yields
AMLX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 20.74% |
| FCF Yield | 3.55% |
Analyst Forecast
The average price target for AMLX is $8, which is 127.3% higher than the current price. The consensus rating is "Hold".
| Price Target | $8 |
| Price Target Difference | 127.3% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -0.89 |
| Piotroski F-Score | 1 |